Cambridge, Massachusetts-based Akebia Therapeutics announced plans to offer and sell about $85 million of its common stock in an underwritten public offering.
The review was requested by the German medicines authority, the Federal Institute for Drugs and Medical Devices (BfArM), and follows a previous EMA review in 2013 which introduced measures to restrict the use of these medicines because of reports of serious liver problems associated with their use.